Drug Trial Radar · NCT07186413
A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
561
Planned (sponsor's estimate)
Start
Sep 23, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.
Conditions
- Acne Vulgaris
Interventions
TrifaroteneDrug
Trifarotene cream applied QD topically.
Vehicle CreamDrug
Vehicle cream applied QD topically.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Investigator Global Assessment (IGA) Success (Face only) at Week 12Time frame: Baseline to Week 12
- Change from Baseline to Week 12 in Facial Non-inflammatory Lesion CountTime frame: Baseline to Week 12
- Change from Baseline to Week 12 in Facial Inflammatory Lesion CountTime frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Galderma Research & Development Site #5378
Shanghai, Jing'an District, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.